Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXAGIST
2018-003998-96Phase 2Active
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab and axitinib in gastrointestinal stromal tumor (GIST), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoint: 3-month progression-free survival rate. Started Feb 2019; status: active.
02
Drugs
avelumabaxitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2018-003998-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003998-96.